Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Dig Dis Sci. 2013 May 30;58(9):2691–2704. doi: 10.1007/s10620-013-2705-y

Fig. 4.

Fig. 4

Cost-effectiveness plane measuring benefit in terms of quality-adjusted life years (QALYs) for all strategies (A–G; see Methods) comparing fibroscan and biopsy for monitoring fibrosis progression in patients with chronic HCV. Dominated strategies are B, C, D, F; E is an extendedly dominated strategy; strategies A and G are on the cost-effective frontier. ICER Incremental cost-effectiveness ratio